Background As known, glucocorticoid-induced osteoporosis is the most common form of osteoporosis. The most pressing issue remains the prevention of osteoporosis in patients with prolonged therapy by glucocorticosteroid. The role of Zoledronic acid (ZOL) for glucocorticoid-induced osteoporosis in patients with inflammatory joints disease remains debatable.
Objectives we aimed to evaluate the effects of Zoledronic acid for glucocorticoid-induced osteoporosis in patients with inflammatory joints disease.
Methods 20 patients (mean age – 57,20±4,46 years) with inflammatory joints disease were enrolled. All patients were women and received glucocorticoid during more than 5 years (mean duration of treatment – 3,20±0,46 years). Women had osteoporosis documented by either a lumbar spine T-score ≤–2.5 or lumbar spine T-score ≤–1.5 with 2 mild or 1 moderate prevalent vertebral fracture. 10 (50%) patients received the standard treatment and Zoledronic acid 5 mg infusion once a year (study group), while 20 (50%) (control group) – received only the standard treatment for 3 years. Visual Analog Scale (VAS), bone mineral density (BMD) were performed in all patients at baseline and at the end of the study.
Results VAS and BMD did not differ significantly between the groups. After 3 years of treatment with Zoledronic acid the incidence of symptoms, including arthralgia were significantly lower in the study in comparison of control groups (P = 0.05). The increase in BMD was greater in the study group than in the control group (P = 0.01). During 3 years among patients in the control group 30% have compression fractures in compare with study group (P = 0.05).
Conclusions Zoledronic acid is effective and safe for patients with glucocorticoid-induced osteoporosis in patients with inflammatory joints disease. Its administration may provide benefits for the reduction of hospitalizations and mortality in its population.
Disclosure of Interest None Declared